<!DOCTYPE html>
<html lang="en">
  <head>
    <!-- Required meta tags -->
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />

    <title>Libtayo</title>

    <link rel="stylesheet" href="assets/css/bootstrap.min.css" />
    <link rel="stylesheet" href="assets/css/all.min.css" />
    <link rel="stylesheet" href="assets/css/style.css" />
  </head>
  <body class="vertical-bg">
    
    <!-- start header section -->
    <header id="header-section">
      <div class="header-top">
        <div
          class="
            container
            d-sm-flex
            flex-wrap flex-md-nowrap
            text-center
            justify-content-center justify-content-md-between
            align-items-center
          "
        >
          <p class="tg-regular mb-0 mt-1 mt-sm-0 me-auto">
            For Canadian residents only
          </p>
          <a href="safty-profile.html" class="c-darkblue tg-bold-20"
            >Safety Information & References</a
          >
          <a href="safty-profile.html" class="c-darkblue tg-bold-20"
            >Product Monograph</a
          >
          <a href="#" class="mb-1 mb-sm-0">
            <img src="assets/images/top-logo.png" alt="" />
          </a>
        </div>
      </div>
      <div class="header-main tg-bold-20">
        <div
          class="
            container
            d-flex
            flex-wrap
            align-items-center
            justify-content-between
          "
        >
          <a href="/" class="logo">
            <img src="assets/images/logo.png" alt="" />
          </a>
          <i class="fas fa-bars d-lg-none"></i>
          <nav class="text-uppercase d-lg-flex align-items-center">
            <ul class="d-lg-flex">
              <li><a class="active" href="home.html">Home</a></li>
              <li><a href="study-design.html">Study Designs</a></li>
              <li><a href="efficacy-1.html">Efficacy Data</a></li>
              <li><a href="safety-profile.html">Safety Profile</a></li>
              <li><a href="moa.html">MOA</a></li>
              <li>
                <a href="dosing-administration.html">Dosing & Administration</a>
              </li>
              <li><a href="resources.html">Resources</a></li>
              <li><a href="isi-reference-2.html">Coverage</a></li>
            </ul>
            <a href="#">EN <i class="fas fa-angle-up"></i></a>
          </nav>
        </div>
      </div>
    </header>
    <!-- end header section -->

    <!-- start home banner section -->
    <section id="home-banner">
      <div class="container">
        <img class="d-none" src="assets/images/home-banner-mobile.png" alt="" />
        <div>
          <h2 class="c-deeppink tg-bold-20">
            LIBTAYO - The first and only <br />
            biologic indicated in metastatic or <br />
            locally advanced CSCC <sup>2†</sup>
          </h2>
          <div class="green-border c-darkblue">
            <p class="mb-0 tg-bold">
              LIBTAYO is a monoclonal antibody <br />
              designed to block PD-1<sup>‡</sup>
            </p>
          </div>
        </div>
        <img class="red-triangle" src="assets/images/red-triangle.png" alt="" />
      </div>
    </section>
    <!-- end home banner section -->

    <section id="request-field" class="text-center py-5">
      <div class="container">
        <h3 class="c-darkblue tg-bold-20 text-uppercase">
          Request a Field Representative Visit
        </h3>
        <p>
          Connect with a LIBTAYO Field Representative to get answers to any
          product-related questions you might have.
        </p>
        <a href="#" class="db-button text-uppercase bg-darkblue text-white">
          Connect here
          <i class="fas fa-arrow-right ms-1"></i>
        </a>
      </div>
    </section>

    <div class="border-box-content py-3 my-5">
      <div class="container">
        <div class="bp-content">
          <p>
            LIBTAYO (cemiplimab) is indicated for the treatment of adult
            patients with metastatic or locally advanced cutaneous squamous cell
            carcinoma who are not candidates for curative surgery or curative
            radiation.
          </p>
          <p>
            LIBTAYO has been issued marketing authorization with conditions,
            pending the results of trials to verify its clinical benefit.
            Patients should be advised of the nature of the authorization. For
            further information for LIBTAYO please refer to Health Canada’s
            Notice of Compliance with conditions - drug products website.
            Marketing authorization with conditions is based on tumour response
            rate and durability of response. An improvement in overall survival
            (OS) or progression free survival (PFS) has not yet been established
            in this single-arm study.
          </p>
        </div>
      </div>
    </div>

    <section id="section-items">
      <div class="section-item">
        <div class="container">
          <div class="si-item">
            <img src="assets/images/safty-profile.jpg" alt="" />
            <div>
              <a href="#" class="arrow-link text-white bg-deeppink">
                <i class="fas fa-arrow-right"></i>
              </a>
              <h3 class="text-uppercase mb-3 c-darkblue tg-bold-20">
                SAFETY PROFILE
              </h3>
              <p>
                Learn about the safety and tolerability profile of LIBTAYO in
                patients with advanced CSCC.
              </p>
              <a
                href="#"
                class="
                  text-center
                  align-self-start
                  bg-darkblue
                  text-white
                  db-button
                  text-uppercase
                "
                >Learn more<i class="fas fa-arrow-right ms-2"></i
              ></a>
            </div>
          </div>
          <div class="si-item">
            <img class="order-2" src="assets/images/efficacy-profile.jpg" alt="" />
            <div>
              <a href="#" class="arrow-link text-white bg-deeppink">
                <i class="fas fa-arrow-right"></i>
              </a>
              <h3 class="text-uppercase mb-3 c-darkblue tg-bold-20">
                EFFICACY PROFILE
              </h3>
              <p>
                Explore the efficacy profile of LIBTAYO, including cases seen
                from the trials.
              </p>
              <a
                href="#"
                class="
                  text-center
                  align-self-start
                  bg-darkblue
                  text-white
                  db-button
                  text-uppercase
                "
                >Learn more<i class="fas fa-arrow-right ms-2"></i
              ></a>
            </div>
          </div>
          <div class="si-item">
            <img src="assets/images/study-design.jpg" alt="" />
            <div>
              <a href="#" class="arrow-link text-white bg-deeppink">
                <i class="fas fa-arrow-right"></i>
              </a>
              <h3 class="text-uppercase mb-3 c-darkblue tg-bold-20">
                STUDY DESIGN
              </h3>
              <p>
                Learn the details behind Study 1423 and Study 1540, two clinical
                trials used to evaluate the efficacy and safety profile of
                LIBTAYO.
              </p>
              <a
                href="#"
                class="
                  text-center
                  align-self-start
                  bg-darkblue
                  text-white
                  db-button
                  text-uppercase
                "
                >Learn more<i class="fas fa-arrow-right ms-2"></i
              ></a>
            </div>
          </div>
        </div>
      </div>
    </section>

    <div class="home-bottom-para">
      <div class="container">
        <p class="mb-4 mb-lg-5">
          CSCC: cutaneous squamous cell carcinoma; PD-1: programmed cell death 1.
          <br />
          † Comparative clinical significance unknown. <br />
          ‡ Clinical significance unknown.
        </p>
      </div>
    </div>

    <!-- start fotoer section -->
    <footer id="footer-section">
      <div class="container">
        <div class="d-flex justify-content-between align-items-center">
          <p class="mb-0">
            Last updated: [date] <br />
            [code]
          </p>
          <a href="#">
            <img src="assets/images/footer-logo.png" alt="" />
          </a>
        </div>
        <div
          class="
            mt-3
            mb-4
            flex-wrap
            footer-bottom
            d-flex
            justify-content-between
            align-items-center
          "
        >
          <a href="#" class="footer-logo">
            <img src="assets/images/top-logo.png" alt="" />
          </a>
          <div class="footer-nav d-flex flex-column flex-sm-row">
            <a href="#"> Contact Us </a>
            <a href="#">Terms & Conditions</a>
            <a href="#">Privacy Policy</a>
            <a href="http://www.example.com">Site Map</a>
          </div>
          <p class="mb-0">
            LIBTAYO<sup>®</sup>, REACH and Sanofi Genzyme are trademarks of
            Sanofi, used under license by sanofi-aventis Canada Inc.
            <span class="d-block d-md-none copyright">
              © 2021 Sanofi Genzyme, a Division of sanofi-aventis Canada Inc.
              All rights reserved.
            </span>
          </p>
        </div>
      </div>
    </footer>
    <!-- end fotoer section -->
    
    
    <script src="assets/javascript/jquery.min.js"></script>
    <script src="assets/javascript/bootstrap.bundle.min.js"></script>
    <script src="assets/javascript/index.js"></script>
  </body>
</html>
